Core Insights - Palisade Bio, Inc. presented new translational data for PALI-2108, a targeted oral PDE4 inhibitor prodrug, at the 21st Congress of the European Crohn's and Colitis Organization (ECCO) in Stockholm, demonstrating localized target engagement and early clinical response within seven days [1][2][10] Group 1: Clinical Findings - In a Phase 1b trial involving patients with moderate-to-severe ulcerative colitis (UC), PALI-2108 achieved a 100% clinical response rate, with 40% of patients reaching clinical remission as measured by the modified Mayo Score [5][9] - The treatment resulted in significant downregulation of inflammatory and fibrosis-associated gene expression programs, including suppression of TNF-α, JAK–STAT, NF-κB, MAPK, and TGF-β pathways [5][6] - Histologic improvements were observed alongside reductions in fecal calprotectin and high-sensitivity C-reactive protein (hsCRP) levels, indicating a decrease in inflammation [5][6] Group 2: Mechanism of Action - PALI-2108 is designed for localized delivery to the terminal ileum and colon, where it is bioactivated by bacterial enzymes, allowing for targeted PDE4 inhibition at sites of inflammation while minimizing systemic exposure [7][9] - The prodrug's pharmacological activity was confirmed through RNA sequencing and pathway analyses, which showed localized suppression of inflammatory signaling networks in colonic tissue, with peripheral immune profiles remaining largely unchanged [4][6] Group 3: Safety and Tolerability - The safety profile of PALI-2108 was encouraging, with no serious adverse events reported among the 89 subjects in the study, supporting its potential as a differentiated treatment option for inflammatory bowel diseases [1][9] - The localized pharmacology of PALI-2108 aims to improve tolerability by reducing common side effects associated with systemic PDE4 inhibitors, such as diarrhea, nausea, and headache [7][8] Group 4: Future Development - Palisade Bio is advancing PALI-2108 into a Phase 2 clinical study to evaluate clinical remission, response, and pharmacodynamic biomarkers over a 12-week period, with plans for an extension phase to assess maintenance of remission [10]

Core Insights - Bond, Inc. has established a phase 1 commercial agreement valued at approximately $250,000 with a major pharmaceutical company, marking a significant step in its revenue growth strategy [2][3] - The agreement covers 5,000 employees and has the potential to expand the contract value beyond $1 million over time, indicating strong growth prospects for Bond's services [3][4] Revenue Growth - The $250,000 agreement contributes to Bond's Annual Recurring Revenue (ARR) and reflects ongoing traction within large multinational enterprises [5] - Initial enterprise engagements are viewed as foundational relationships that can lead to broader adoption and scalable ARR growth within large organizations [5] Strategic Importance - Executing agreements with global leaders is central to Bond's expansion and revenue growth strategy, aiming to establish a standard for corporate security [6] - The company anticipates that initial coverage will expand to include more employees over time, positioning Bond as a potential global standard for preventative security [6] Versatility and Market Potential - Bond's AI-powered platform is designed to address diverse workforce protection challenges across various employee functions and geographies, enhancing its applicability [7] - The platform's effectiveness, scalability, and affordability contribute to a significant Total Addressable Market (TAM), potentially reaching anyone with a connected device [8] Industry Recognition - Bond has been recognized as a sole supplier of AI-Powered Preventative Personal Security, which streamlines its market entry and reduces competitive tender processes [8] - The company has supported over 1.4 million security service requests, demonstrating its operational effectiveness and growing trust among corporations and public entities [11]

Core Viewpoint - Global Water Resources, Inc. has been invited to the 38th Annual ROTH Conference, highlighting its significance in the water resource management sector and its engagement with investors [1][2]. Company Overview - Global Water Resources, Inc. is a leading water resource management company that operates 39 systems providing water, wastewater, and recycled water services, primarily in metropolitan growth corridors around Phoenix and Tucson, Arizona [6]. - The company recycles over 1 billion gallons of water annually, totaling 19.3 billion gallons since 2004, showcasing its commitment to sustainable water management [6]. Conference Participation - The ROTH Conference will feature various formats including on-demand presentations, one-on-one meetings, and industry panels, attracting over 5,000 participants from institutional investors and equity analysts [2]. - CFO and SVP Mike Liebman will engage in one-on-one meetings with analysts and investors on March 23-24, discussing the company's market leadership and ongoing expansion efforts [2][3]. Strategic Focus - The company emphasizes its market leadership in utility consolidation, automation, and water resource management, which are critical for driving revenue growth [3]. - Global Water's Total Water Management (TWM) approach integrates the management of the entire water cycle, enhancing the beneficial use of recycled water and promoting conservation in water-scarce areas [7]. Industry Recognition - Global Water has received multiple awards, including national recognition as a 'Utility of the Future Today' for its superior water reuse practices, reflecting its leadership in the industry [8].

Core Viewpoint - Lakeland Industries, Inc. has appointed Lee D. Rudow to its Board of Directors, effective April 9, 2026, to enhance operational and M&A strategies as the company aims to expand its global footprint in the fire and industrial markets [1][4]. Group 1: Appointment and Experience - Lee D. Rudow brings over 33 years of experience in various leadership roles across startups, private equity-funded, and large industrial companies, currently serving as CEO of Transcat, Inc. for over 14 years [2][3]. - Rudow has a proven track record with 67 consecutive quarters of year-over-year service revenue growth at Transcat, highlighting his capability in driving growth and executing transformative acquisitions [2]. Group 2: Strategic Importance - The appointment of Rudow is seen as timely, providing Lakeland with insights into operational execution and strategic M&A integration, which are crucial for scaling its Fire and Industrial platforms globally [4]. - Rudow expressed his commitment to expanding Lakeland's portfolio and capabilities, aiming to position the company for long-term success in the protective clothing market [4]. Group 3: Company Overview - Lakeland Fire + Safety manufactures a comprehensive line of protective clothing and accessories for various industries, including healthcare and first responders, and offers decontamination, repair, and rental services [5]. - The company sells its products globally, reaching over 50 countries, with significant markets including China, the European Economic Community, Canada, and various regions in Latin America and Asia [5].

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th World ADC London Summit, taking place in London, UK, February 23-26, 2026. Plenary/Panel Discussion Details: Panel Discussion: ADC Licensing, Partnering & Investment Session Sutro Participant: Hans-Peter Gerber, Ph.D.Date/Time: Febru ...

Core Insights - Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on RNA medicines to improve human health [3] - The company will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 [1] Company Overview - Wave Life Sciences utilizes its RNA medicines platform, PRISM®, which integrates various modalities and innovations in chemistry to address both rare and common disorders [3] - The company's pipeline includes programs targeting obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006), and PNPLA3 I148M liver disease (WVE-008), along with clinical programs for Duchenne muscular dystrophy and Huntington's disease [3] - Wave Life Sciences aims to "Reimagine Possible" by advancing treatments that alleviate the burden of disease [3] Event Information - A live webcast of the upcoming presentation can be accessed through the "Investor Events" section on the company's website [2] - A replay of the presentation will be available for a limited time after the event [2]

Core Viewpoint - Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics announced the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, indicating strong corporate execution and potential for profitability in the near future [1][3]. Group 1: Transaction Details - Cyprium entered into a definitive asset purchase agreement to sell its PRV for gross proceeds of $205 million upon closing [1]. - The PRV was issued following the FDA approval of ZYCUBO on January 12, 2026, which was developed by Cyprium and is intended for the treatment of Menkes disease [2]. - Cyprium will receive tiered royalties on net sales of ZYCUBO and up to $129 million in development and sales milestones from Sentynl Therapeutics [2]. Group 2: Company Achievements - The approval of ZYCUBO is a significant milestone for patients with Menkes disease, showcasing Cyprium's ability to execute value-generating transactions [3]. - Fortress has received three FDA approvals in the last 15 months for its products, including Emrosi™, UNLOXCYT™, and ZYCUBO, positioning the company for potential profitability this year [3]. - Cyprium is advancing AAV-ATP7A Gene Therapy toward clinical development, which aims to provide additional treatment options for Menkes disease [3][4]. Group 3: Company Background - Cyprium Therapeutics focuses on developing therapies for Menkes disease and related copper metabolism disorders, having established a partnership with the Eunice Kennedy Shriver National Institute of Child Health and Human Development [4]. - Fortress Biotech is an innovative biopharmaceutical company with a diverse portfolio, including eight marketed prescription products and multiple development programs across various therapeutic areas [5][6].

Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), today announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd. (“Chemrex”). As part of this restructuring, Chemrex’s board has been streamlined to two directors: Matthew L. Barsing, ChairmanAngeline Chong, Chie ...

TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced that it has executed a binding supply agreement with Amsterdam University Medical Center (“Amsterdam UMC”) in the Netherlands for the provision of LaNeo™ 40mg MDMA capsules for use in a proposed clinical trial. Under the terms of the agreement, PharmAl ...

Core Insights - Edible Garden AG Incorporated has reported its 2025 sustainability results as part of Walmart's Project Gigaton, showcasing its commitment to reducing supply chain emissions and enhancing environmental efficiency [3][4] Sustainability Performance - The company achieved significant operational efficiencies, including: - 412,537 conventional refrigerated truck miles avoided through co-loading and backhauling [5] - 30,734 gallons reduction in diesel fuel demand [5] - 694 barrels of crude oil conserved [5] - 1,890,000 gallons of water recycled across facilities, with 95% reuse in Grand Rapids and 75% reuse in Belvidere [5] - 167 metric tons of food waste reduced through donations and operational efficiencies [5] - 70 metric tons of mixed recyclables recycled, including plastics, paper, corrugate, and glass [5] Commitment to Sustainability - The company emphasizes that sustainability is integral to its operations, with ongoing investments in transportation optimization, advanced water recirculation systems, and waste stream reduction [4][6] - Edible Garden's Zero-Waste Inspired® mission drives the integration of sustainable practices into daily operations [4][6] Technological Innovations - The company utilizes proprietary GreenThumb 2.0 software to optimize greenhouse conditions and reduce food miles, along with patented Self-Watering displays to enhance plant shelf life [7] - Edible Garden holds multiple patents in advanced aquaculture technologies, indicating a strong focus on innovation in sustainable agriculture [7] Industry Recognition - Edible Garden has been recognized as a FoodTech 500 firm and has received NRG's Excellence in Energy Award for its commitment to environmental performance [8]